Arbutus Biopharma Corporation (ABUS): Price and Financial Metrics


Arbutus Biopharma Corporation (ABUS): $2.68

-0.16 (-5.63%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ABUS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ABUS POWR Grades


  • Sentiment is the dimension where ABUS ranks best; there it ranks ahead of 92.23% of US stocks.
  • The strongest trend for ABUS is in Stability, which has been heading down over the past 179 days.
  • ABUS's current lowest rank is in the Stability metric (where it is better than 10.39% of US stocks).

ABUS Stock Summary

  • Of note is the ratio of Arbutus Biopharma Corp's sales and general administrative expense to its total operating expenses; merely 8.13% of US stocks have a lower such ratio.
  • The ratio of debt to operating expenses for Arbutus Biopharma Corp is higher than it is for about merely 8.15% of US stocks.
  • ABUS's price/sales ratio is 40.72; that's higher than the P/S ratio of 95.6% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Arbutus Biopharma Corp are CLLS, ALPN, MGNX, SYRS, and SGTX.
  • ABUS's SEC filings can be seen here. And to visit Arbutus Biopharma Corp's official web site, go to www.arbutusbio.com.

ABUS Valuation Summary

  • In comparison to the median Healthcare stock, ABUS's EV/EBIT ratio is 115.7% lower, now standing at -4.6.
  • Over the past 142 months, ABUS's price/earnings ratio has gone up 1.4.
  • ABUS's price/sales ratio has moved up 37.4 over the prior 142 months.

Below are key valuation metrics over time for ABUS.

Stock Date P/S P/B P/E EV/EBIT
ABUS 2021-08-31 40.7 3.4 -4.0 -4.6
ABUS 2021-08-30 40.1 3.3 -4.0 -4.5
ABUS 2021-08-27 39.5 3.3 -3.9 -4.4
ABUS 2021-08-26 38.6 3.2 -3.8 -4.3
ABUS 2021-08-25 38.7 3.2 -3.8 -4.3
ABUS 2021-08-24 38.6 3.2 -3.8 -4.3

ABUS Growth Metrics

    The 3 year price growth rate now stands at -43.32%.
  • The 2 year price growth rate now stands at -75.59%.
  • Its 5 year revenue growth rate is now at -67.19%.
Over the past 52 months, ABUS's revenue has gone up $3,017,000.

The table below shows ABUS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 10.988 -67.532 -88.386
2021-09-30 10.168 -62.939 -86.656
2021-06-30 8.351 -59.077 -84.193
2021-03-31 7.536 -53.869 -78.622
2020-12-31 6.914 -51.441 -75.868
2020-09-30 6.146 -49.779 -83.237

ABUS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ABUS has a Quality Grade of D, ranking ahead of 23.96% of graded US stocks.
  • ABUS's asset turnover comes in at 0.061 -- ranking 309th of 681 Pharmaceutical Products stocks.
  • ABBV, PLXP, and HSTO are the stocks whose asset turnover ratios are most correlated with ABUS.

The table below shows ABUS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.061 1 -1.012
2021-03-31 0.059 1 -1.139
2020-12-31 0.059 1 -1.030
2020-09-30 0.056 1 -1.204
2020-06-30 0.073 1 -2.668
2020-03-31 0.053 1 -3.000

ABUS Price Target

For more insight on analysts targets of ABUS, see our ABUS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.90 Average Broker Recommendation 1.7 (Moderate Buy)

ABUS Stock Price Chart Interactive Chart >

Price chart for ABUS

ABUS Price/Volume Stats

Current price $2.68 52-week high $6.50
Prev. close $2.84 52-week low $1.93
Day low $2.63 Volume 928,500
Day high $2.86 Avg. volume 1,928,570
50-day MA $2.48 Dividend yield N/A
200-day MA $3.27 Market Cap 398.59M

Arbutus Biopharma Corporation (ABUS) Company Bio


Arbutus Biopharma Corporation, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of chronic hepatitis B (HBV) infections in Canada and the United States. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. The company is based in Burnaby, Canada.


ABUS Latest News Stream


Event/Time News Detail
Loading, please wait...

ABUS Latest Social Stream


Loading social stream, please wait...

View Full ABUS Social Stream

Latest ABUS News From Around the Web

Below are the latest news stories about Arbutus Biopharma Corp that investors may wish to consider to help them evaluate ABUS as an investment opportunity.

Halozyme Therapeutics (HALO) Q4 Earnings and Revenues Surpass Estimates

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 5% and 5.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 22, 2022

Arbutus to Report Fourth Quarter and Year End 2021 Financial Results and Provide Corporate Update

WARMINSTER, Pa., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its fourth quarter and year end 2021 financial results and corporate update for Thursday, March 3, 2022. The schedule for the press release and conference call/webcast are as follows: •Q4 and Year End 2021 Press

Yahoo | February 17, 2022

Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q4 Loss, Tops Revenue Estimates

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -1.34% and 3.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 8, 2022

What's the Outlook for Arbutus Biopharma?

The company could have great prospects if its hepatitis B virus therapy is successful in clinical testing.

Yahoo | February 5, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Welcome back, trader!

William White on InvestorPlace | January 31, 2022

Read More 'ABUS' Stories Here

ABUS Price Returns

1-mo 8.06%
3-mo -10.07%
6-mo -30.93%
1-year -20.47%
3-year 28.85%
5-year -26.58%
YTD -31.11%
2021 9.58%
2020 27.70%
2019 -27.42%
2018 -24.16%
2017 106.12%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6544 seconds.